Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Digital
- Autores:
-
Schwartz, Gregory G.
Szarek, Michael
Bittner, Vera A.
Diaz, Rafael
Goodman, Shaun G.
Jukema, J. Wouter
Landmesser, Ulf
López-Jaramillo, Patricio
Manvelian, Garen
Pordy, Robert
Scemama, Michel
Sinnaeve, Peter R.
White, Harvey D.
Steg, Gabriel
ODYSSEY Outcomes Committees and Investigators
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2021
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/6065
- Acceso en línea:
- https://doi.org/10.1016/j.jacc.2021.04.102
https://repositorio.udes.edu.co/handle/001/6065
- Palabra clave:
- Acute coronary syndrome
Lipoprotein(a)
Low-density lipoprotein cholesterol
PCSK9 inhibitor
- Rights
- openAccess
- License
- Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
id |
RUDES2_138e63eb064dc56cbe635e56107329ef |
---|---|
oai_identifier_str |
oai:repositorio.udes.edu.co:001/6065 |
network_acronym_str |
RUDES2 |
network_name_str |
Repositorio Universidad de Santander |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol |
title |
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol |
spellingShingle |
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol Acute coronary syndrome Lipoprotein(a) Low-density lipoprotein cholesterol PCSK9 inhibitor |
title_short |
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol |
title_full |
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol |
title_fullStr |
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol |
title_full_unstemmed |
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol |
title_sort |
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol |
dc.creator.fl_str_mv |
Schwartz, Gregory G. Szarek, Michael Bittner, Vera A. Diaz, Rafael Goodman, Shaun G. Jukema, J. Wouter Landmesser, Ulf López-Jaramillo, Patricio Manvelian, Garen Pordy, Robert Scemama, Michel Sinnaeve, Peter R. White, Harvey D. Steg, Gabriel ODYSSEY Outcomes Committees and Investigators |
dc.contributor.author.none.fl_str_mv |
Schwartz, Gregory G. Szarek, Michael Bittner, Vera A. Diaz, Rafael Goodman, Shaun G. Jukema, J. Wouter Landmesser, Ulf López-Jaramillo, Patricio Manvelian, Garen Pordy, Robert Scemama, Michel Sinnaeve, Peter R. White, Harvey D. Steg, Gabriel ODYSSEY Outcomes Committees and Investigators |
dc.contributor.researchgroup.spa.fl_str_mv |
Masira |
dc.subject.proposal.eng.fl_str_mv |
Acute coronary syndrome Lipoprotein(a) Low-density lipoprotein cholesterol PCSK9 inhibitor |
topic |
Acute coronary syndrome Lipoprotein(a) Low-density lipoprotein cholesterol PCSK9 inhibitor |
description |
Digital |
publishDate |
2021 |
dc.date.issued.none.fl_str_mv |
2021-08-03 |
dc.date.accessioned.none.fl_str_mv |
2022-02-21T14:04:52Z |
dc.date.available.none.fl_str_mv |
2022-02-21T14:04:52Z |
dc.type.spa.fl_str_mv |
Artículo de revista |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.content.spa.fl_str_mv |
Text |
dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
http://purl.org/coar/resource_type/c_6501 |
status_str |
publishedVersion |
dc.identifier.ark.none.fl_str_mv |
https://doi.org/10.1016/j.jacc.2021.04.102 |
dc.identifier.uri.none.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/6065 |
url |
https://doi.org/10.1016/j.jacc.2021.04.102 https://repositorio.udes.edu.co/handle/001/6065 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationendpage.spa.fl_str_mv |
433 |
dc.relation.citationissue.spa.fl_str_mv |
5 |
dc.relation.citationstartpage.spa.fl_str_mv |
421 |
dc.relation.citationvolume.spa.fl_str_mv |
78 |
dc.relation.indexed.spa.fl_str_mv |
Scopus |
dc.relation.ispartofjournal.spa.fl_str_mv |
Journal of the American College of Cardiology |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
dc.format.extent.spa.fl_str_mv |
13 p |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Elsevier |
dc.publisher.place.spa.fl_str_mv |
USA |
dc.source.spa.fl_str_mv |
https://www.sciencedirect.com/science/article/pii/S0735109721052475?via%3Dihub |
institution |
Universidad de Santander |
bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/3d225395-f4a0-4b4f-912e-d8922e034266/download https://repositorio.udes.edu.co/bitstreams/fb7d32b6-87d4-4089-9aac-972d51b3d30a/download https://repositorio.udes.edu.co/bitstreams/eb275252-0c94-4774-9305-edd649ce77b7/download https://repositorio.udes.edu.co/bitstreams/f9af28d1-7ef9-49b0-a38e-de17310ae33f/download |
bitstream.checksum.fl_str_mv |
019378d936c8be8c381b45b6f7257deb 38d94cf55aa1bf2dac1a736ac45c881c 5dbe86c1111d64f45ba435df98fdc825 49455d060d06b2b29d1bd2e0b2531f82 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Universidad de Santander |
repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
_version_ |
1814159020326387712 |
spelling |
Schwartz, Gregory G.0b9e6dfc-0a1d-4287-aee3-7713fce86ece-1Szarek, Michaele170e054-026f-4b96-a3f9-bf538a71553f-1Bittner, Vera A.ab899d35-5158-4520-b79d-4e866540846e-1Diaz, Rafaelf2be4a74-501a-4e63-8bbd-965cbcf8c57b-1Goodman, Shaun G.7f7d25ba-48f2-4592-8b03-25be06199175-1Jukema, J. Woutere6ea1e4d-1059-465c-b34b-854ca0141a3e-1Landmesser, Ulfe2fd9c4a-a4e2-4cfa-82fe-82a9528084c3-1López-Jaramillo, Patriciof72eca20-6f41-45fe-a875-83c14605cb60-1Manvelian, Garen4313214f-cf48-4faa-a446-3961d8c5de48-1Pordy, Robertadb5a1bc-eeb7-4d31-bab1-bd073aa4d3e7-1Scemama, Michel6c3278cc-a589-4cc5-a2b1-d9ab678b83c4-1Sinnaeve, Peter R.f438e55b-0c51-485e-a6d4-9cbd6d9a6b03-1White, Harvey D.88cf0d68-0edb-4f0b-9457-53b047230cd0-1Steg, Gabriel5e15ab0e-e531-446a-8adf-a24611c97076-1ODYSSEY Outcomes Committees and Investigators18d1e891-7825-4987-8cab-b78c84a15489-1Masira2022-02-21T14:04:52Z2022-02-21T14:04:52Z2021-08-03DigitalBackground Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. Objectives In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, the authors evaluated the benefit of adding the proprotein subtilisin/kexin type 9 inhibitor alirocumab to optimized statin treatment in patients with LDL-C levels near 70 mg/dL. Effects were evaluated according to concurrent lipoprotein(a) levels. Methods ODYSSEY Outcomes compared alirocumab with placebo in 18,924 patients with recent acute coronary syndromes receiving optimized statin treatment. In 4,351 patients (23.0%), screening or randomization LDL-C was <70 mg/dL (median 69.4 mg/dL; interquartile range: 64.3-74.0 mg/dL); in 14,573 patients (77.0%), both determinations were ≥70 mg/dL (median 94.0 mg/dL; interquartile range: 83.2-111.0 mg/dL). Results In the lower LDL-C subgroup, MACE rates were 4.2 and 3.1 per 100 patient-years among placebo-treated patients with baseline lipoprotein(a) greater than or less than or equal to the median (13.7 mg/dL). Corresponding adjusted treatment hazard ratios were 0.68 (95% confidence interval [CI]: 0.52-0.90) and 1.11 (95% CI: 0.83-1.49), with treatment-lipoprotein(a) interaction on MACE (Pinteraction = 0.017). In the higher LDL-C subgroup, MACE rates were 4.7 and 3.8 per 100 patient-years among placebo-treated patients with lipoprotein(a) >13.7 mg/dL or ≤13.7 mg/dL; corresponding adjusted treatment hazard ratios were 0.82 (95% CI: 0.72-0.92) and 0.89 (95% CI: 0.75-1.06), with Pinteraction = 0.43. Conclusions In patients with recent acute coronary syndromes and LDL-C near 70 mg/dL on optimized statin therapy, proprotein subtilisin/kexin type 9 inhibition provides incremental clinical benefit only when lipoprotein(a) concentration is at least mildly elevated. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402)Ciencias Médicas y de la Salud13 papplication/pdfhttps://doi.org/10.1016/j.jacc.2021.04.102https://repositorio.udes.edu.co/handle/001/6065engElsevierUSA433542178ScopusJournal of the American College of Cardiology© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.info:eu-repo/semantics/openAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2https://www.sciencedirect.com/science/article/pii/S0735109721052475?via%3DihubAcute coronary syndromeLipoprotein(a)Low-density lipoprotein cholesterolPCSK9 inhibitorLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL CholesterolArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdfLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdfapplication/pdf253228https://repositorio.udes.edu.co/bitstreams/3d225395-f4a0-4b4f-912e-d8922e034266/download019378d936c8be8c381b45b6f7257debMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/fb7d32b6-87d4-4089-9aac-972d51b3d30a/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdf.txtLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/eb275252-0c94-4774-9305-edd649ce77b7/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdf.jpgLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdf.jpgGenerated Thumbnailimage/jpeg12240https://repositorio.udes.edu.co/bitstreams/f9af28d1-7ef9-49b0-a38e-de17310ae33f/download49455d060d06b2b29d1bd2e0b2531f82MD54001/6065oai:repositorio.udes.edu.co:001/60652023-10-09 16:53:24.719https://creativecommons.org/licenses/by-nc/4.0/© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |